ASK-120067
- Generic Name
- ASK-120067
A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.
Phase 2
Not yet recruiting
- Conditions
- EGFR Mutation Positive Advanced Non Small Cell Lung CancerPD-L1 Positive
- Interventions
- Drug: Limertinib+bevacizumab
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 136
- Registration Number
- NCT06982924
Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects
Phase 1
Completed
- Conditions
- Locally Advanced or Metastatic NSCLC
- Interventions
- Dietary Supplement: ASK120067 in fed condition
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04360915
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
Phase 3
Active, not recruiting
- Conditions
- Locally Advanced or Metastatic NSCLC
- Interventions
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 337
- Registration Number
- NCT04143607
- Locations
- 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
🇨🇳Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Chest Hospital,Capital Medical University, Beijing, Beijing, China
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 507
- Registration Number
- NCT03502850
- Locations
- 🇨🇳
Beijing Chest Hospital,Capital Medical University, Beijing, Beijing, China
🇨🇳Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath